Medicare Rate Hike Lifts Insurers, Humira Discount Shakes Up

Health insurers rally on larger-than-expected 2027 Medicare Advantage payment increase

Healthcare Market Overview

$JNJ delivered the best first-quarter performance among all S&P 500 healthcare stocks, signaling potential momentum into a new growth era. Health insurers climbed broadly after the government announced a larger-than-expected increase in 2027 Medicare Advantage payment rates, with $UNH receiving upgrades and appearing among active after-hours movers. The sector showed broad-based strength despite ongoing pricing pressures on legacy therapies.

Big Pharma & Biotech

$ABBV launched Humira on the TrumpRx platform with an 86% discount under a White House pricing agreement, marking a significant shift in its post-exclusivity US pricing strategy. The stock closed at $206.69 with a 1-year return of 14.5%, though shares dropped 1.03% despite broader market gains. $LLY received price target increases following FDA approval for Fundayo, though modelled fair value was trimmed slightly to $1,209.21 per share as analysts reframe investment narratives around GLP-1 pricing and obesity opportunity valuations. $REGN won FDA approval to extend Eylea HD dosing intervals to 20 weeks for wet AMD and DME patients. $MRNA announced it will present late-breaking revaccination data for its investigational seasonal influenza vaccine mRNA-1010 and mRESVIA at ESCMID 2026.

MedTech & Devices

$ISRG was highlighted among market-beating stocks with competitive advantages, noted for its ability to sustain rising sales, expanding margins, and increasing returns on capital over extended periods. No other major medical device or diagnostics developments were reported in today's data.

FDA & Regulation

$REGN secured FDA approval for extended Eylea HD dosing intervals to 20 weeks, providing greater treatment flexibility while reinforcing efforts to offset declining legacy Eylea sales. The Centers for Medicare & Medicaid Services announced a larger-than-expected increase in 2027 Medicare Advantage payment rates, benefiting approximately 35 million beneficiaries currently enrolled in Medicare Advantage plans. Pharma and biotech giants ramped up M&A activity in Q1 2026 to counter patent pressures and expand pipelines through billion-dollar deals and AI innovation partnerships.

Looking Ahead

$MRNA will present revaccination data for its investigational seasonal influenza vaccine and mRESVIA at ESCMID 2026. Investors are monitoring how the Medicare Advantage rate increase will flow through to managed care earnings, with $UNH positioned as a key beneficiary. Pharma M&A momentum is expected to continue as companies like $LLY and $MRK pursue pipeline expansion to address patent cliffs and tap into emerging therapeutic areas.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy